Providence Capital Advisors’s Moderna MRNA Stock Holding History

Providence Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15	Closed	-$2K	–	324
2022 Q3	$2K	Buy	+15	New	+$2.28K	﹤0.01%	286

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Providence Capital Advisors's MRNA Position: Q4 2022 in Review

Providence Capital Advisors sold out of Moderna (MRNA) in Q4 2022, closing a stake of 15 shares — an estimated $2K sold.

Providence Capital Advisors first reported a position in MRNA in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

Providence Capital Advisors reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
Providence Capital Advisors sold 15 Moderna shares in Q4 2022, an estimated $2K.
Providence Capital Advisors first reported a position in Moderna in Q3 2022 and held it in 1 quarter.
Providence Capital Advisors's Moderna position peaked at $2K in Q3 2022.
1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Providence Capital Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.